SCHEMBL1552893

SCHEMBL1552893

Cc1c[nH]c2cc(C(=O)O)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.53
PDE4B Q07343 1/20 0.53
PDE4C Q08493 1/20 0.53
PDE4D Q08499 1/20 0.53
SPR P35270 1/20 0.49
PTPN1 P18031 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
THRB P10828 1/20 0.47
HSD17B10 Q99714 2/20 0.47
ENPP2 Q13822 1/20 0.47
DYRK1A Q13627 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
HSP90AA1 P07900 1/20 0.46
ESR2 Q92731 1/20 0.46
ATM Q13315 1/20 0.46
NOTUM Q6P988 1/20 0.46
GPR183 P32249 1/20 0.45
HTR7 P34969 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159543 1.00 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DSPR
Hydrochloric Acid SCHEMBL8602502 0.98 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DSPR
SCHEMBL14572835 0.86 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL2610249 0.86 HTR7 (0.56) PTPN1KDM4EALDH1A1HPGDTHRB
SCHEMBL31200443 0.84 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL8602499 0.84 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DSPR
SCHEMBL7403240 0.84 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL6419348 0.81 F7 (0.51) SPRPTPN1KDM4EALDH1A1HPGD
SCHEMBL16810634 0.81 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL21824244 0.81 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233111-B2 Pyrrolo pyrimidine derivatives NOVARTIS AG (CH) 2016-01-12 US claimed
EP-2729466-B1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2015-08-19 EP claimed
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2014-08-28 US claimed
EP-2729466-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2014-05-14 EP claimed
WO-2013008095-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2013-01-17 WO claimed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 CN disclosed
WO-2024179405-A1 CLASS OF CINNAMAMIDE DERIVATIVES AND APPLICATION THEREOF 上海交通大学 2024-09-06 WO disclosed
CN-118546081-A Cinnamide derivative and application thereof 上海交通大学 2024-08-27 CN disclosed
WO-2024158872-A1 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF THE ROCKEFELLER UNIVERSITY (US) 2024-08-02 WO disclosed
CN-115260180-B Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2024-05-28 CN disclosed
US-20240109915-A1 NOVEL ACC INHIBITORS PFIZER INC. (US) 2024-04-04 US disclosed
EP-3632898-B1 EP4 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2023-07-12 EP disclosed
WO-2001096304-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed
WO-2001096323-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed
US-6303600-B1 USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY RHONE-POULENC RORER LIMITED (GB) 2001-10-16 US disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
WO-2000076971-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
EP-0934307-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1999-08-11 EP disclosed
WO-1998005327-A1 SUBSTITUTED AROMATIC COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-12 WO disclosed
WO-1997048697-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109915-A1 NOVEL ACC INHIBITORS CBR3, NAT1, ACACB PDE4A 4715/4885PDE4B 4673/4885PDE4C 4732/4885
US-20140243306-A1 NOVEL PYRROLO PYRIMIDINE DERIVATIVES BTK, LCK, ZAP70 PDE4A 794/4885PDE4B 756/4885PDE4C 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.